title: Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification.
abstract: The role of hyperphosphatemia in the pathogenesis of secondary hyperparathyroidism, cardiovascular disease, and progression of renal failure is widely known. Here we studied effects of dietary phosphate restriction on mortality and vascular calcification in uremic rats. Control and uremic rats were fed a high-phosphate diet and at 3 months a portion of rats of each group were killed. Serum phosphate and the calcium phosphate product increased in uremic rats, as did aortic calcium. Of the rats, 56% had positive aortic staining for calcium (von Kossa), RUNX2, and osteopontin. The remaining uremic rats were continued on diets containing high phosphate without and with sevelamer, or low phosphate, and after 3 more months they were killed. Serum phosphate was highest in uremic rats on high phosphate. Serum PTH and FGF-23 were markedly lower in rats on low phosphate. Mortality on high phosphate was 71.4%, with sevelamer reducing this to 37.5% and phosphate restriction to 5.9%. Positive aortic staining for von Kossa, RUNX2, and osteopontin was increased, but phosphate restriction inhibited this. Kidneys from low-phosphate and sevelamer-treated uremic rats had less interstitial fibrosis, glomerulosclerosis, and inflammation than those of uremic rats on high phosphate. Importantly, kidneys from rats on low phosphate showed improvement over kidneys from high-phosphate rats at 3 months. Left ventricles from rats on low phosphate had less perivascular fibrosis and smaller cardiomyocyte size compared to rats on high phosphate. Thus, intensive phosphate restriction significantly reduces mortality in uremic rats with severe vascular calcification.
authors.affiliation: Renal Division, Washington University School of Medicine, St Louis, Missouri, USA.
authors.forename: Jane L
authors.initials: JL
authors.lastname: Finch
authors.forename: Duk H
authors.initials: DH
authors.lastname: Lee
authors.forename: Helen
authors.initials: H
authors.lastname: Liapis
authors.forename: Cindy
authors.initials: C
authors.lastname: Ritter
authors.forename: Sarah
authors.initials: S
authors.lastname: Zhang
authors.forename: Edu
authors.initials: E
authors.lastname: Suarez
authors.forename: Leon
authors.initials: L
authors.lastname: Ferder
authors.forename: Eduardo
authors.initials: E
authors.lastname: Slatopolsky
mesh_terms: D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D015415:Biomarkers / Q000097:blood; D002118:Calcium / Q000378:metabolism; D002614:Chelating Agents / Q000494:pharmacology; D050659:Core Binding Factor Alpha 1 Subunit / Q000378:metabolism; D004032:Diet; D004195:Disease Models, Animal; D005260:Female; D005346:Fibroblast Growth Factors / Q000097:blood; D005355:Fibrosis; D054559:Hyperphosphatemia / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D007668:Kidney / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D053495:Osteopontin / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000008:administration & dosage / Q000097:blood / Q000172:deficiency*; D011073:Polyamines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D000069603:Sevelamer; D013997:Time Factors; D014511:Uremia / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D061205:Vascular Calcification / Q000209:etiology / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*
chemical_list: D015415:Biomarkers; D002614:Chelating Agents; D050659:Core Binding Factor Alpha 1 Subunit; C505605:Fgf23 protein, rat; D010281:Parathyroid Hormone; D010710:Phosphates; D011073:Polyamines; C493717:Runx2 protein, rat; C506897:Spp1 protein, rat; D053495:Osteopontin; D005346:Fibroblast Growth Factors; D000069603:Sevelamer; D002118:Calcium